Retinal Diseases: Emerging Therapies and Vision Rehabilitation

Dear Colleagues,

Retinal diseases are among the leading causes of visual impairment and blindness worldwide, affecting vast numbers of people and posing a serious public health challenge. Recent advances in biomedical research have led to the development of diverse novel therapeutic strategies, including gene therapy, stem cell–based treatments, neuroprotective agents, innovative pharmacological approaches, and surgical interventions. At the same time, efforts have been made to refine and optimize the application of existing treatments to address the limitations and challenges of newly developed therapies. Furthermore, for cases in which these interventions alone cannot restore sufficient visual function, vision rehabilitation—integrating advanced optical devices, digital technologies, and personalized training programs—has played a vital role in improving patients’ functional vision and quality of life (QoL).

This Special Issue, “Retinal Diseases: Emerging Therapies and Vision Rehabilitation,” aims to share knowledge that will enhance the understanding and application of best clinical practices, ultimately contributing to improvements in patient outcomes and quality of life. Looking ahead, it seeks to highlight the latest advances with the potential to expand the possibilities for retinal disease treatment, with the ultimate goal of making a meaningful contribution to the fight against vision loss.

Prof. Dr. Hisanori Imai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.